JP2018517735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517735A5 JP2018517735A5 JP2017565133A JP2017565133A JP2018517735A5 JP 2018517735 A5 JP2018517735 A5 JP 2018517735A5 JP 2017565133 A JP2017565133 A JP 2017565133A JP 2017565133 A JP2017565133 A JP 2017565133A JP 2018517735 A5 JP2018517735 A5 JP 2018517735A5
- Authority
- JP
- Japan
- Prior art keywords
- dmf
- particles
- particle
- less
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 32
- 229960004419 dimethyl fumarate Drugs 0.000 claims 32
- 239000002245 particle Substances 0.000 claims 27
- 239000002552 dosage form Substances 0.000 claims 7
- 239000012528 membrane Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 102000057297 Pepsin A Human genes 0.000 claims 1
- 108090000284 Pepsin A Proteins 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 238000007922 dissolution test Methods 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 230000000887 hydrating effect Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229940111202 pepsin Drugs 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021184469A JP2022042512A (ja) | 2015-06-17 | 2021-11-12 | フマル酸ジメチル粒子及びそれらの医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181061P | 2015-06-17 | 2015-06-17 | |
| US62/181,061 | 2015-06-17 | ||
| PCT/US2016/037486 WO2016205270A1 (en) | 2015-06-17 | 2016-06-15 | Dimethyl fumarate particles and pharmaceutical compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184469A Division JP2022042512A (ja) | 2015-06-17 | 2021-11-12 | フマル酸ジメチル粒子及びそれらの医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517735A JP2018517735A (ja) | 2018-07-05 |
| JP2018517735A5 true JP2018517735A5 (enExample) | 2019-07-18 |
Family
ID=56292916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565133A Pending JP2018517735A (ja) | 2015-06-17 | 2016-06-15 | フマル酸ジメチル粒子及びそれらの医薬組成物 |
| JP2021184469A Pending JP2022042512A (ja) | 2015-06-17 | 2021-11-12 | フマル酸ジメチル粒子及びそれらの医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021184469A Pending JP2022042512A (ja) | 2015-06-17 | 2021-11-12 | フマル酸ジメチル粒子及びそれらの医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11291642B2 (enExample) |
| EP (1) | EP3310341A1 (enExample) |
| JP (2) | JP2018517735A (enExample) |
| KR (1) | KR20180018711A (enExample) |
| CN (1) | CN107920997A (enExample) |
| AU (2) | AU2016279997B2 (enExample) |
| CA (1) | CA2989581A1 (enExample) |
| EA (1) | EA201890068A1 (enExample) |
| HK (1) | HK1254054A1 (enExample) |
| IL (1) | IL256296A (enExample) |
| MA (1) | MA42196A (enExample) |
| MX (1) | MX387092B (enExample) |
| WO (1) | WO2016205270A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072699A1 (en) * | 2015-10-28 | 2017-05-04 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| KR20180108814A (ko) * | 2016-02-11 | 2018-10-04 | 바이오젠 엠에이 인코포레이티드 | 다이메틸 퓨마레이트를 포함하는 약제학적 비드 제형 |
| EP3691616A1 (en) * | 2017-10-02 | 2020-08-12 | Novartis AG | Method for preparing a pharmaceutical product |
| US11318682B2 (en) | 2018-04-06 | 2022-05-03 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3D) object printing based on build material permeability |
| EP3860849A4 (en) * | 2018-10-05 | 2022-06-22 | ISP Investments LLC | SMOOTH HIGH SOLIDS FILM COATING COMPOSITION WITH WATER SOLUBLE CELLULOSE ETHER, PROCESS FOR ITS PRODUCTION |
| TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
| AU2020214626B2 (en) * | 2019-01-31 | 2025-10-16 | Elektrofi, Inc. | Particle formation and morphology |
| EP3941445A4 (en) | 2019-03-20 | 2023-08-02 | Lyndra Therapeutics, Inc. | CAPSULES AND CAPSULE COATINGS FOR GASOLINE DOSAGE FORMS |
| EP3941444B1 (en) * | 2019-03-20 | 2025-03-26 | Lyndra Therapeutics, Inc. | Coatings for gastric residence dosage forms |
| JP2023553274A (ja) * | 2020-11-18 | 2023-12-21 | エフビー－エイチアールエス リミテッド ライアビリティ カンパニー | ドフェチリド及びメキシレチンを含有する組成物並びにその使用 |
| US20220175812A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| JP2024516108A (ja) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術 |
| AU2022285951A1 (en) | 2021-06-04 | 2024-01-04 | Zim Laboratories Limited | Delayed release compositions of dimethyl fumarate |
| US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025090498A1 (en) * | 2023-10-23 | 2025-05-01 | Isp Investments Llc | Encapsulated medium chain fatty acid salts and oral solid dosage forms derived therefrom |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| DE14172396T1 (de) * | 2004-10-08 | 2015-01-08 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
| US8298574B2 (en) | 2006-01-18 | 2012-10-30 | Intec Pharma Ltd. | Method and apparatus for forming delivery devices for oral intake of an agent |
| ES2606395T3 (es) | 2008-04-18 | 2017-03-23 | Intec Pharma Ltd. | Administración de fármacos gastrorretentivos para carbidopa/levodopa |
| CN102369000A (zh) * | 2009-01-09 | 2012-03-07 | 前进制药公司 | 包含一种或多种富马酸酯的药用组合物 |
| CN109044985A (zh) | 2009-01-09 | 2018-12-21 | 前进制药知识产权有限公司 | 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂 |
| MX355421B (es) * | 2011-06-08 | 2018-04-18 | Biogen Ma Inc | Proceso para preparar fumarato de dimetilo cristalino y de alta pureza. |
| WO2013076216A1 (en) * | 2011-11-24 | 2013-05-30 | Synthon Bv | Controlled release particles comprising dimethyl fumarate |
| AU2013203445C1 (en) * | 2012-02-07 | 2017-04-20 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| US9840456B2 (en) * | 2013-09-25 | 2017-12-12 | Glenmark Pharmaceuticals Limited | Process for preparation of dimethyl fumarate |
| US10172794B2 (en) * | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
| EP3501510B1 (en) * | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
-
2016
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Ceased
- 2016-06-15 HK HK18113117.1A patent/HK1254054A1/zh unknown
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/en not_active Withdrawn
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 MX MX2017016509A patent/MX387092B/es unknown
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/en not_active Ceased
- 2016-06-15 CA CA2989581A patent/CA2989581A1/en active Pending
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517735A5 (enExample) | ||
| JP6105761B2 (ja) | 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法 | |
| ES2688889T3 (es) | Proceso de mezcla sin disolvente para el recubrimiento de ingredientes farmacéuticos | |
| KR20190107712A (ko) | 특정 위장 부위에서의 제어 방출의 투여 형태 | |
| JP2014528431A5 (enExample) | ||
| KR20180018711A (ko) | 디메틸 푸마레이트 입자 및 이들의 약제학적 조성물 | |
| JP2016514686A5 (enExample) | ||
| RU2015110825A (ru) | Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола | |
| JP2009525300A5 (enExample) | ||
| WO2014144661A4 (en) | Rapidly dispersible dosage form of topiramate | |
| JP2007510677A (ja) | 調節性の物質の放出に影響を及ぼすマトリックスを有する多層の剤形 | |
| JP2016516698A5 (enExample) | ||
| JP2016513724A5 (enExample) | ||
| JP2012505884A5 (enExample) | ||
| WO2015193788A1 (en) | Formulation for oral administration containing mesalazine | |
| CN103228676B (zh) | 羟烷基纤维素 | |
| JP2014503523A5 (enExample) | ||
| CN110035744A (zh) | 一种尼拉帕尼缓控释药物组合物及其用途 | |
| EA031255B1 (ru) | Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения | |
| TW200635617A (en) | Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form | |
| JP2018516266A5 (enExample) | ||
| JP2012082195A5 (enExample) | ||
| HRP20231012T1 (hr) | Novi sastav s odgođenim oslobađenjem za peroralno davanje | |
| ES2661062T3 (es) | Procedimiento de preparación de partículas huecas y sus aplicaciones | |
| RU2009137911A (ru) | Порошки для создания жирной лекарственной формы |